Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.
The idiotype of myeloma immunoglobulin can be used as a unique tumour-specific antigen. We tested the hypothesis that tumour antigen-specific immunity can be transferred from bone-marrow-transplant donor to recipient. We immunised a healthy sibling donor with myeloma immunoglobulin from the plasma of the recipient, conjugated to an immunogenic carrier protein and emulsified in an adjuvant, before marrow transplantation. Detection of a lymphoproliferative response, a parallel response in the carrier protein, recovery of a recipient CD4+ T-cell line with unique specificity for myeloma idiotype, and demonstration by in-situ hybridisation that the cell line was of donor origin, proved that a myeloma idiotype-specific T-cell response was successfully transferred to the recipient. Donor immunisation with myeloma idiotype may represent a new strategy for enhancing the specific anti-tumour effect of allogeneic marrow grafts.
Kwak
L W
LW
Biological Response Modifiers Program, National Cancer Institute, Frederick, MD 21702-1201, USA.
Taub
D D
DD
Duffey
P L
PL
Bensinger
W I
WI
Bryant
E M
EM
Reynolds
C W
CW
Longo
D L
DL
D000328:Adult; D016026:Bone Marrow Transplantation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology* / Q000601:surgery*; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D014611:Vaccination
D007130:Immunoglobulin Idiotypes